AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24063608 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine plus piperaquine
Number of subjects: 100
Study 24063608 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 20304980 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride
Number of subjects: 372
Study 20304980 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% Lidocaine
Number of subjects: 372
Study 20304980 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine
Number of subjects: 372
Study 20304980 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Saline
Number of subjects: 372
Study 18664256 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 222
Study 18664256 — intervention group
Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 222
Study 16824239 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine
Number of subjects: 72
Study 16824239 — intervention group
Group type: COMPARATOR
Intervention: 0.25% ropivacaine
Number of subjects: 72
Study 16824239 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% ropivacaine
Number of subjects: 72
Study 16824239 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including 0.25% levobupivacaine, 0.25% ropivacaine, and 0.4% ropivacaine)
Number of subjects: 72
Study 12492710 — intervention group
Group type: EXPERIMENTAL
Intervention: One dose of daclizumab (2 mg/kg)
Number of subjects: 12
Study 12492710 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of daclizumab (2nd dose, 1 mg/kg)
Number of subjects: 12
Study 12492710 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab levels of 1 micro g/mL or greater
Number of subjects: 12
Study 10977382 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco control activities in intervention communities
Number of subjects: 22
Study 10977382 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth tobacco control activities in intervention communities
Number of subjects: 22
Study 10977382 — intervention group
Group type: COMPARATOR
Intervention: Comparison communities
Number of subjects: 22
Study 8771523 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine
Number of subjects: 3117
Study 8771523 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver nitrate
Number of subjects: 3117
Study 8771523 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin
Number of subjects: 3117
Study 8771523 — intervention group
Group type: COMPARATOR
Intervention: Maternal vaginitis
Number of subjects: 3117
Study 1591091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment for 5 years
Number of subjects: 504
Study 1591091 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (six courses of cyclophosphamide, methotrexate and 5‐fluorouracil (CMF) followed by 4 courses of epirubicin)
Number of subjects: 504
Study 1591091 — intervention group
Group type: COMPARATOR
Intervention: Combination of chemotherapy and tamoxifen
Number of subjects: 504
Study 1591091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 504
Study 1591091 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent or sequential use of chemotherapy and tamoxifen
Number of subjects: 504
Study 30457209 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite genetic risk score (GRS) based on 27 single nucleotide polymorphisms (SNPs)
Number of subjects: 1640
Study 30457209 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 1640
Study 30457209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1640
Study 28302387 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation (2 mA, 10 sessions over 2 weeks)
Number of subjects: 40
Study 28302387 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct-current stimulation (10 sessions over 2 weeks)
Number of subjects: 40
Study 28302387 — intervention group
Group type: EXPERIMENTAL
Intervention: Active transcranial direct-current stimulation
Number of subjects: 40
Study 28302387 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct-current stimulation
Number of subjects: 40
Study 25462207 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic harp sounds (30-40 minutes of prescriptive live therapeutic harp sounds)
Number of subjects: 92
Study 25462207 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 92
Study 25462207 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic harp sounds
Number of subjects: 92
Study 23656489 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback interventions (Fb)
Number of subjects: 133
Study 23656489 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 133
Study 21860048 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensatory cognitive training (CT)
Number of subjects: 89
Study 19650422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) method
Number of subjects: 295
Study 19650422 — intervention group
Group type: COMPARATOR
Intervention: Burch suspension
Number of subjects: 295
Study 19650422 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods (Burch and TVT)
Number of subjects: 295
Study 17263741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 113
Study 17263741 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 113
Study 17263741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (0-24 months)
Number of subjects: 113
Study 15209619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 5 mg orally three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Number of subjects: 82
Study 15209619 — intervention group
Group type: COMPARATOR
Intervention: Placebo three times daily for 12 weeks (dose doubled after 4 weeks if no improvement)
Number of subjects: 82
Study 15209619 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 82
Study 15209619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 11136204 — intervention group
Group type: EXPERIMENTAL
Intervention: High UPA score practices
Number of subjects: 18414
Study 11136204 — intervention group
Group type: COMPARATOR
Intervention: Low UPA score practices
Number of subjects: 18414
Study 9588577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 20
Study 9588577 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin + Cyclosporine
Number of subjects: 20
Study 8019118 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% nedocromil sodium
Number of subjects: 64
Study 8019118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 2731558 — intervention group
Group type: EXPERIMENTAL
Intervention: Full contrast dose (282 mg I/kg body weight)
Number of subjects: 60
Study 2731558 — intervention group
Group type: COMPARATOR
Intervention: Half contrast dose (141 mg I/kg body weight)
Number of subjects: 60
Study 4381149 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 0
Study 4381149 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium pemoline
Number of subjects: 0
Study 4381149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31654654 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavanol-rich cocoa beverage (FC)
Number of subjects: 14
Study 31654654 — intervention group
Group type: COMPARATOR
Intervention: Non-flavanol containing beverage (NF)
Number of subjects: 14
Study 31295390 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush with CrissCross and tapered bristle technology (Oral-B CrossAction Ultrathin); brushed twice daily for 4 weeks.
Number of subjects: 100
Study 31295390 — intervention group
Group type: COMPARATOR
Intervention: Traditional flat-trim design and regular non-tapered bristles (Oral-B Indicator Soft 35); brushed twice daily for 4 weeks.
Number of subjects: 100
Study 31295390 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tapered and control toothbrushes); assessed for plaque reduction using TMQHPI.
Number of subjects: 100
Study 28045890 — intervention group
Group type: EXPERIMENTAL
Intervention: Postal pedometer intervention
Number of subjects: 1023
Study 28045890 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-supported pedometer intervention
Number of subjects: 1023
Study 28045890 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 1023
Study 26176621 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First with Intensive Case Management (HF with ICM)
Number of subjects: 378
Study 23384637 — intervention group
Group type: EXPERIMENTAL
Intervention: High-school education
Number of subjects: 2951
Study 23384637 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic education
Number of subjects: 2951
Study 23384637 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue collar occupation
Number of subjects: 2951
Study 23384637 — intervention group
Group type: COMPARATOR
Intervention: Academic/white collar occupations
Number of subjects: 2951
Study 21303430 — intervention group
Group type: EXPERIMENTAL
Intervention: 16μg lubiprostone
Number of subjects: 170
Study 21303430 — intervention group
Group type: EXPERIMENTAL
Intervention: 32μg lubiprostone
Number of subjects: 170
Study 21303430 — intervention group
Group type: EXPERIMENTAL
Intervention: 48μg lubiprostone
Number of subjects: 170
Study 21303430 — intervention group
Group type: EXPERIMENTAL
Intervention: 48μg lubiprostone (patients with IBS)
Number of subjects: 170
Study 21303430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 19179885 — intervention group
Group type: EXPERIMENTAL
Intervention: PBP (ProBioPlus DDS, UAS Laboratories)
Number of subjects: 90
Study 19179885 — intervention group
Group type: EXPERIMENTAL
Intervention: CUL (Culturelle, ConAgra)
Number of subjects: 90
Study 19179885 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dilute preparation of Pregestamil formula)
Number of subjects: 90
Study 19179885 — intervention group
Group type: EXPERIMENTAL
Intervention: PBP
Number of subjects: 90
Study 19179885 — intervention group
Group type: EXPERIMENTAL
Intervention: CUL
Number of subjects: 90
Study 19179885 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 17658695 — intervention group
Group type: EXPERIMENTAL
Intervention: Freshmen-specific personalized normative feedback (PNF)
Number of subjects: 316
Study 17658695 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 316
Study 14688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA)
Number of subjects: 1614
Study 14688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) in smokers
Number of subjects: 1614
Study 14688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) in non-smokers
Number of subjects: 1614
Study 14688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) with cumulative smoking dose
Number of subjects: 1614
Study 14688021 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant SULT1A1 genotype (638GA or AA) across histological subtypes
Number of subjects: 1614
Study 11825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 11825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 11825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac
Number of subjects: 0
Study 11825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0
Study 11825322 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam
Number of subjects: 0
Study 9331014 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (4-16 mg once-daily)
Number of subjects: 0
Study 7944681 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone therapy
Number of subjects: 67
Study 7944681 — intervention group
Group type: COMPARATOR
Intervention: Not receiving amiodarone
Number of subjects: 67
Study 2908757 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidamidine hydrochloride
Number of subjects: 72
Study 30109702 — intervention group
Group type: EXPERIMENTAL
Intervention: Active TFP block
Number of subjects: 20
Study 30109702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TFP and LFC nerve blockade
Number of subjects: 20
Study 30109702 — intervention group
Group type: EXPERIMENTAL
Intervention: TFP block
Number of subjects: 20
Study 30109702 — intervention group
Group type: COMPARATOR
Intervention: Placebo TFP block
Number of subjects: 20
Study 28972039 — intervention group
Group type: EXPERIMENTAL
Intervention: Galinpepimut-S with GM-CSF and Montanide
Number of subjects: 41
Study 28972039 — intervention group
Group type: COMPARATOR
Intervention: Control adjuvants (GM-CSF and Montanide alone)
Number of subjects: 41
Study 25539281 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational brochure
Number of subjects: 120
Study 23206722 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous posterior tibial nerve stimulation (TPTNS)
Number of subjects: 30
Study 23206722 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (placebo)
Number of subjects: 30
Study 21964277 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (flexible doses) for up to 14 weeks
Number of subjects: 2876
Study 19109962 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg) administered intravenously within 4 weeks of surgery and continued for 1 year
Number of subjects: 24
Study 19109962 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17821878 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby Express newsletter
Number of subjects: 185
Study 17821878 — intervention group
Group type: COMPARATOR
Intervention: Normal services only (control)
Number of subjects: 185
Study 16343130 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually-selected enhancement parameters for video
Number of subjects: 0
Study 16343130 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive enhancement (individually-tuned using a static image)
Number of subjects: 0
Study 16343130 — intervention group
Group type: EXPERIMENTAL
Intervention: Stronger contrast enhancement
Number of subjects: 0
Study 16343130 — intervention group
Group type: COMPARATOR
Intervention: Unenhanced, over-enhanced, and degraded segments
Number of subjects: 0
Study 12411229 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning
Number of subjects: 65
Study 12411229 — intervention group
Group type: COMPARATOR
Intervention: Conventional instruction
Number of subjects: 65
Study 10467830 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg/day for 3 months)
Number of subjects: 10
Study 7605028 — intervention group
Group type: EXPERIMENTAL
Intervention: Antishock overalls (ASO)
Number of subjects: 30
Study 7605028 — intervention group
Group type: COMPARATOR
Intervention: Traditional antishock intensive care
Number of subjects: 30
Study 2319316 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with adjuvant chemotherapy (CCNU, vincristine, and prednisone)
Number of subjects: 233
Study 2319316 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 233
Study 2319316 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CCNU, vincristine, and prednisone) in patients with more extensive tumors
Number of subjects: 233
Study 2319316 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (radiation therapy with and without chemotherapy)
Number of subjects: 233
Study 536969 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg twice a day
Number of subjects: 101
Study 536969 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg twice a day
Number of subjects: 101
Study 536969 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of propranolol and bendrofluazide
Number of subjects: 101
Study 536969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 30651036 — intervention group
Group type: EXPERIMENTAL
Intervention: Udenafil 75 mg daily
Number of subjects: 138
Study 31320603 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum sealing drainage (VSD) treatment combined with skin flap transplantation and antibiotic bone cement
Number of subjects: 18
Study 28396306 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based intervention for physical activity (PA) and fruit and vegetable intake (FVI) over 8 weeks.
Number of subjects: 493
Study 25803642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivalent NoV VLP vaccine (genotypes GI.1/GII.4)
Number of subjects: 10
Study 24210087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (100 mg daily)
Number of subjects: 171
Study 24210087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Number of subjects: 171
Study 24210087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 21732905 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-hMG
Number of subjects: 155
Study 21732905 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 155
Study 19565549 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment plus rheumatologic care program
Number of subjects: 181
Study 19565549 — intervention group
Group type: COMPARATOR
Intervention: Rheumatologic care program
Number of subjects: 181
Study 16782719 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (50 or 70 microg/kg/min) for 3 hours starting within 15 minutes of reperfusion therapy
Number of subjects: 0
Study 16782719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15307977 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH), specifically dalteparin
Number of subjects: 28
Study 15307977 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 28
Study 11402974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine (10 mg/day)
Number of subjects: 605
Study 11402974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 605
Study 11402974 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine
Number of subjects: 605
Study 9124466 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (steroidogenic enzyme inhibitor)
Number of subjects: 0
Study 8066317 — intervention group
Group type: EXPERIMENTAL
Intervention: Decontaminated vinyl urinary drainage bags (group E)
Number of subjects: 88
Study 8066317 — intervention group
Group type: COMPARATOR
Intervention: Weekly replaced vinyl urinary drainage bags (group C)
Number of subjects: 88
Study 3113764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (NTG) continuous infusion
Number of subjects: 31
Study 3113764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 30604373 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE‐IBD system (self-testing every other week)
Number of subjects: 222
Study 30604373 — intervention group
Group type: EXPERIMENTAL
Intervention: TELE‐IBD system (self-testing weekly)
Number of subjects: 222
Study 30604373 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 222
Study 29509614 — intervention group
Group type: EXPERIMENTAL
Intervention: Boss-Holzach-Matter self-reduction technique (BHM group)
Number of subjects: 60
Study 29509614 — intervention group
Group type: COMPARATOR
Intervention: Spaso technique (Sp group)
Number of subjects: 60
Study 26538205 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 + PPI (celecoxib 200 mg twice daily + rabeprazole 20 mg once daily)
Number of subjects: 57
Study 26538205 — intervention group
Group type: COMPARATOR
Intervention: COX-2 + placebo (celecoxib 200 mg twice daily + placebo)
Number of subjects: 57
Study 26538205 — intervention group
Group type: EXPERIMENTAL
Intervention: COX-2 + PPI
Number of subjects: 57
Study 26538205 — intervention group
Group type: COMPARATOR
Intervention: COX-2 + placebo
Number of subjects: 57
Study 24949820 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 973
Study 24949820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 973
Study 24949820 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident delayed filling
Number of subjects: 973
Study 24949820 — intervention group
Group type: EXPERIMENTAL
Intervention: No incident delayed filling
Number of subjects: 973
Study 24949820 — intervention group
Group type: COMPARATOR
Intervention: Monthly treatment
Number of subjects: 973
Study 24949820 — intervention group
Group type: COMPARATOR
Intervention: As needed treatment
Number of subjects: 973
Study 22130905 — intervention group
Group type: EXPERIMENTAL
Intervention: Relapse prevention therapy (RPT)
Number of subjects: 81
Study 22130905 — intervention group
Group type: COMPARATOR
Intervention: Specialist FEP care
Number of subjects: 81
Study 21300221 — intervention group
Group type: EXPERIMENTAL
Intervention: Damon3 self-ligated brackets
Number of subjects: 62
Study 21300221 — intervention group
Group type: COMPARATOR
Intervention: Synthesis conventional ligated brackets
Number of subjects: 62
Study 19225121 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MM) supplementation (1-1.5 times the Recommended Dietary Allowance of vitamins A, B-6, B-12, C, folic acid, iron, zinc, and other nutrients) 6 d/wk from 3 to 24 mo of age
Number of subjects: 650
Study 19225121 — intervention group
Group type: COMPARATOR
Intervention: Iron only in utero and Fe-A during childhood
Number of subjects: 650
Study 16881095 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative interventions for lateral epicondylitis
Number of subjects: 349
Study 12482641 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 46
Study 12482641 — intervention group
Group type: COMPARATOR
Intervention: Control (diet or metformin)
Number of subjects: 46
Study 11395985 — intervention group
Group type: EXPERIMENTAL
Intervention: High calcium group (dairy food supplementation)
Number of subjects: 91
Study 11395985 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dairy food supplementation)
Number of subjects: 91
Study 8383397 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (2.5 mg o.d. initially, increased to 5 mg and 10 mg o.d.)
Number of subjects: 0